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Results: A total 30 cases in the age group of 14 to 57 years (median
age of 28 years) were studied.
Out of the 30 cases 27 were males and remaining 3 were fe-
males. In 25 cases out of 30 (83%), the Femoral Vein was medial to
Artery. In 5 cases (17%) the Femoral Vein was Postero-medial to
the femoral artery. Among the 5 cases 2 cases had more than 50%
overlap. No one had femoral vein completely posterior to femoral
artery. In our study themean Femoral artery size was 7.3 mm (SD-
1.4) in Antero-posterior dimension and 7.5 mm (SD -1.4) in hori-
zontal dimension. This has important implications while cannu-
lating the artery for vascular access.
Conclusion: We conclude that there is a distinct variation in the
anatomical location of the femoral artery and vein. In 17% of in-
dividuals the vein is located Postero-medial to the artery, among
them one third have significant overlap (>50%) of artery and vein.
This may have implicate during the femoral artery access.
Safety and efficiency of eptifibatide in primary
angioplasty patients with renal insufficiency
V.S.R. Bhupal, M. Jyotsna, D. Seshagiri Rao
Nizam's Institue of Medical Sciences, Hyderabad, India
Aim: Eptifibatide adjustment of dosage is required in renal
insufficiency patients. But when we do not know the renal status
in primary angioplasty patients with significant intracoronary
thrombus, wewant to study the safety and efficacy of normal dose
of Eptifibatide.
Methods: We analyzed the Patients who had Primary angioplasty
with significant intracoronary thrombus with renal insufficiency
(calculated GFR < 60 ml/min) and received bolus dose of Eptifi-
batide 180 microgram/kg followed by infusion of 2.0 microgram/
kg/min for 12 hours. All patients in addition received loading
dose of clopidogrel 600mg and Aspirin 325 mg. In all patients
Platelet aggregation was tested after Primary angioplasty with
chronology dual aggregometer (optical density dependent) with
ADP (sustained inhibition of 10 mmol/L ADP induced aggregation).
After knowing the basal serum creatinine levels, Glomerular
filtration rate (GFR) was calculated using Cockroft & Gault for-
mula (140-Age (yrs)) weight (Kgs) / S.creatinineX72 *(X0.85
correction for women).
Results: Number of primary angioplasty patients who received
Eptifibatide who’s GFR is <60 ml/min were 53 patients. Males
were 43 and females were 10 with mean age of 59±10 years. Out
of them only diabetics were 7 (13.2%), only hypertensive were 19
(35.9%) and both diabetic and hypertensive with or without
smoking in 27 (50.9%) patients. Mean platelet inhibition after
primary PCI was 95±2%. PCI to LAD in 23 (43.4%), LCX/ ramus in
10 (18.9%), RCA in 5 (9.4%) and two culprit lesions in 15 (28.3%)
patients were done. Mean GFR in this group was 45±9ml/min and
mean creatinine 1.6±0.4mg/dl. 2 (3.8%) patients had worsening of
pre existing CKD possibly related to contrast (in both cases serum
creatinine shooted to 2 mg/dl). Both of them recovered without
any need for dialysis. Nne had either puncture site or non-
puncture bleeding. Six patients required IABP and 2 required
temporary pacing.
Conclusion: Even though we do not know the underlying renal
status in primary angioplasty pts (who really have renal insuffi-
ciency) we can give routine dose of Eptifibatide to maintain effi-
ciency without compromising safety.
Drug eluting balloon evaluation in de-novo non-
LAD stenoses
J.S. Hiremath, K.S. Sheth, C.N. Makhale
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Background: Drug eluting balloons (DEB) are preferred therapy in
cases of In-stent restenosis. However their efficacy in cases of de-
novo lesions is yet to be acceptably established.
Methods: 25 random individuals with de-novo non eLAD critical
stenoses (>70% angiographic stenosis) underwent coronary an-
gioplasty with Sequent Please (Paclitaxel Eluting) Balloon between
11 May 2012 to 18 December 2012.Additional lesions in other
coronaries were treated in the same sitting with drug eluting or
bare metal stents. At 9 month post-procedure, all underwent
coronary angiography irrespective of the symptoms.
Results: Twenty five lesions were treatedwith DEB. DEB procedure
was successful in all patients. One required stenting with DES due
to dissection.At 9month angiographic follow-up, all patients were
free of angina. One patient had critical restenosis. Incidentally 2
patients had in-stent restenosis in BMS and DES in other vessels
but DEB segment was widely patent.
Our study group had 100% procedural success (DEB) with 96%
post-procedure patency rate at nine month angiographic follow-
up. Complication rate for the procedure was 4% (TIMIminor bleed)
and in-segment restenosis was 4%. During the same period,
restenosis rate for stents was 8% (2 in 24 stents) (Surprisingly
higher than DEB).
Conclusion: DEB in small to medium non eLAD critical stenoses is
safe and effective procedure.
Efficiency of bivalirudin in improving coronary
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Aim: To see whether Bivalirudin alone improve the coronary flow
before PCI.
Methods: We prospectively recruited patients of acute coronary
syndrome (ACS) excluding ST elevation MI with single significant
coronary stenosis (not complete occlusion) undergoing percuta-
neous coronary intervention (PCI). Immediately after basal culprit
vessel angiogram in a appropriate view, Bivalirudin 0.75 mg/kg
intravenous bolus followed by a 1.75kg/mg hour infusion was
started. Then again in same previous view culprit vessel angio-
gram was repeated 3 minutes after stating the Bivallirudin infu-
sion. TIMI frame count was taken as indicator of coronary flow.
TIMI fram count (till the last segment of that particular vessel) of
culprit vessel was noted from angiogram at basal and after Biva-
lirudin injection. We excluded the angio analysis of cases where
there is improper engagement of guide catheter or guide sizes
other than 6F.
Results: In 50 eligible ACS patients lesion was in LAD in 23 (46%),
LCX in 15 (30%) and RCA in 12(24%). Mean TIMI frame count before
Bivalirudin was 16.92± 6.2 vs 11.4±3.8 , three minutes after start-
ing the Bivalirudin infusion which is statistically significant (p¼<
0.0001). There were no PCI procedure related complications like
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